INTERLEUKIN-2 INDUCED ANTINEOPLASTIC PEPTIDE

Abstract: Methods and compositions are provided for production of novel polypeptides having antineoplastic activity. Polypeptides are obtained by lymphokine activation of killer lymphocytes, solubilizing peptides from the cells with acidic ethanolic extraction and purification using chromatography. The resulting peptides may be prepared by other techniques, such as synthesis or expression in nonmammalian or mammalian host cells. The peptides find use in inhibition of neoplastic cell proliferation.

Description: While the immune system appears to include neoplastic cells in its repertoire of alien cells to be attacked and destroyed, the increasing incidence of malignancy requiring external intervention evidences the limitations of the natural protection. While chemotherapy has demonstrated its ability to extend the lives of many tumor patients and in many instances provide cures, nevertheless, chemotherapy by itself or in conjunction with radiation involves heroic measures. The drugs and irradiation frequently have extensive side effects, resulting in depression of the immune system, susceptibility to opportunistic infection, loss of hair, fatigue, and a substantially reduced ability to function. Tumor necrosis factor cachexin has recently been shown to have specific antineoplastic activity. Other naturally occurring compounds produced in mammalian hosts have also been found to have preferential inhibitory effects with neoplastic cells as compared with normal cells. How the body uses these compounds to control neoplasia has not been elucidated. The probability is that more than one compound is involved. Natural killer cells are known to be effective in killing tumor cells. The particular mechanism by which these cells control the growth and proliferation of tumor cells is unknown. It would be of substantial interest to understand how natural killer cells exhibit their cytotoxic activity and, whether individual compounds can be isolated which could be used in conjunction with the natural immune system to enhance the natural protection to destroy neoplastic cells. Evidence that lymphocytes with anticancer activity in vitro can have such activity in vivo and induce tumor regression was reported by Hellstrom, et al ., Proc. 8th Canadian Cancer Conf. (1969) 425-442. Rosenberg and his associates at the National Cancer Institute have found that IL-2 stimulated lymphocytes (LAK cells) can inhibit the outgrowth of tumor cells. See, for example, Rosenberg, et al ., New England J. Med. (1985) 313 :1485-1492; Rosenberg, J. Natl. Cancer Inst. (1985) 75 :595-603; Rayner, et al ., J. Natl. Cancer Inst. (1985) 75 :67-75; Lafreniere and Rosenberg, Cancer Res. (1985) 3735-3741; Ettinghausen, et al ., J. Immunol. (1985) 135 :3623-3635; and Shu and Rosenberg, J. Immunol. (1985) 135 :2895-2903. An acid-stable polypeptide of apparent molecular weight in the range of about 15 to 22 kiloDaltons (kD) is obtained from interleukin-2 activated T-lymphocytes. The polypeptide can be purified on reverse phase HPLC using aqueous acidic acetonitrile as eluent. The polypeptide is found to have preferential inhibitory activity toward neoplastic cells. Novel acid-stable polypeptides are provided which are capable of isolation from interleukin-2 activated T-lymphocytes. The novel polypeptides have an apparent molecular weight of from about 15 to 22kD as determined by TSK250 HPLC sizing chromatography under conditions which disfavor aggregation, i.e., 40% acetonitrile and low pH, 0.05% trifluoroacetic acid. The novel polypeptides elute from a reverse phase HPLC C₁₈ µ-Bondapak column at 42-43% (uncorrected) acetonitrile in 0.05% aqueous trifluoroacetic acid, pH 1.9. The subject compounds may be found in T-cells of various mammalian species, including mouse, primate, human, bovine, rat, or rabbit. Peripheral blood lymphocytes free of red blood cells may be combined in an appropriate medium with IL-2, generally from about 1-5x10⁻³ units of IL-2 being employed per cell, with a cellular concentration of about 10⁵-10⁸ cells per ml. The T-cell and IL-2 containing culture medium may then be incubated at moderate temperatures of about 20 to 38°C in air having an elevated carbon dioxide concentration, about 5% carbon dioxide, for an extended period of time, usually not exceeding 5 days, usually 3 days. Nonadherent cells may be collected from the cell suspension by centrifugation. The cells are primarily T-cells and appear to have a dark granular color, whereas cultures not pretreated with interleukin do not. The source of the lymphocytes may be any peripheral blood lymphocyte source such as spleen or lymph nodes. The particular source is not critical, splenocytes being convenient. The cellular peptides may be solubilized from the IL-2 treated T-lymphocytes (LAK lymphocyte-activated killer cells) utilizing acid ethanol extraction. (Roberts, et al ., Proc. Natl. Acad. Sci. USA (1980) 77 :3493) After extraction and centrifugation, supernatants may be pooled, and the solution partially neutralized to a pH in the range of 5 to 5.5, and the ammonium acetate buffer added resulting in a precipitate, which is removed. The supernatant is then combined with cold anhydrous ether and cold ethanol at a reduced temperature (about -20°C) and the resulting precipitate isolated. Further purification can be achieved using reverse phase, high performance liquid chromatography (Marquardt and Todaro, J. Biol. Chem. (1982) 257 :5220). Aqueous acidic acetonitrile may be employed for gradient elution and the eluting peptides monitored by isolating individual fractions. The subject polypeptides, fragments thereof having physiological activity, and analogs thereof, differing by fewer than 5%, usually differing by fewer than 2%, and preferably differing by fewer than 1% in amino acid number, while retaining physiological activity, may be employed in the subject invention. The fragments will at least have immunological activity, being cross-reactive with the naturally occurring peptide. Usually fragments will be at least 8 amino acids, more usually at least 12 amino acids, and may be 30 amino acids or more. Analogs may have conservative or nonconservative substitutions, deletions, insertions, or may be conjugated to a wide variety of peptides or proteins. By conservation substitutions is intended replacement of one amino acid by another, where the steric and polar considerations have not been significantly changed. Illustrative of conservative substitutions are G,A; V,I,L; S, T; D,E; N,Q; K,L; and F,W,Y. Usually, nonconservative substitutions will be fewer than 2%, more usually fewer than 1%, and may be limited to from 1 to 5 amino acids. The subject peptides may be joined to a wide variety of proteins, which may serve as immunogens to provide for production of polyclonal or monoclonal antibodies to the subject proteins. The immunogenic proteins will usually be from a different species from the subject peptides (heterologous) and greater than about 30kD. Illustrative immunogenic proteins include bovine serum albumin, keyhold limpet hemocyanin, β-globin, and soybean trypsin inhibitor. Methods of conjugating two peptides are well known, where bifunctional compounds may be used, such as glutaraldehyde, maleididobenzoic acid, methyldithioacetic acid. Methods of immunizing a vertebrate host for the production of specific antibodies are well known and do not require discussion here. The subject peptides may be prepared by means other than lymphokine activation of killer cells. The subject peptides may be synthesized in accordance with conventional techniques, there being a wide variety of synthetic methods and apparatuses available. Alternatively, the subject peptides may be prepared by introducing a gene expressing a fragment or all of the naturally occurring peptide into a host where the gene is under the regulatory control of transcriptional initiation and termination regions which are functional in the host. A wide variety of hosts find use, including bacterial, e.g., E. coli , B. subtilis , yeast, filamentous fungi, or other unicellular microorganisms mammalian cells such as mouse cells, monkey cells, or human cells. Various expression constructs have been described in the literature and may be employed with the advantage for genes expressing the peptides of this invention. The subject compounds may be used in vitro and as medicaments. In vitro , the subject compounds may be used to inhibit the proliferation of tumor cells in mixtures of cells. Thus, the subject compounds can be used in cultures where it is desired to free a mixture of normal and neoplastic cells from the neoplastic cells. Illustrative situations include the removal of bone marrow from a mammalian host for removal of any neoplastic cells and return of the bone marrow to the host. The subject compounds may be used in reducing the rate Of growth of tumors in vitro . The subject compounds may be employed in vivo by themselves or in conjunction with other compounds to inhibit the proliferation of neoplastic cells, by injecting the subject compounds into the bloodstream, subcutaneously, intralesionally, intraperitoneally, or intramuscularly. The subject compounds may also be used in diagnostic tests, being used in competitive assays for detection of the naturally occurring compound in physiological fluids or cells. The subject compounds may also be used for titrating receptors for the subject compounds in order to determine the likelihood of response to the subject compounds. The subject compounds may be formulated in conventional ways, in physiologically acceptable fluids such as distilled water, saline, or phosphate-buffered saline, depending upon the use of the naturally occurring compound or analogs or fragments thereof. The naturally occurring compound can be obtained at purities of at least 10%, preferably at least 20%, more preferably at least 30%, and desirably 90% or greater. The compounds can be obtained free of cellular compounds, such as debris, membranes, organelles, other cellular proteins, and the like. Compositions can be attained having activities as described in the experimental section of at least about 100-200mg, preferably at least about half maximal inhibition of 5x10⁴ tumor cells per 10mg of polypeptide per ml. The antineoplastin of at least 90% purity with a minimum activity for selected tumor cells from cancer of the lung, colon and breast is capable of inhibiting the growth of 50% of the cells at 10-100ng per milliliter as determined by the growth inhibitor assay. The following examples are offered by way of illustration. EXPERIMENTAL Materials and Methods Preparation of Lymphokine-Activated Killer (LAK) Cells Spleens were removed from C57BL female mice aseptically and mascerated with a loose dounce. The mascerated spleens were then forced through a 100-mesh Mytex grid and centrifuged for 5min at 1500rpm. Red blood cells were lysed by resuspension in Tris-buffered ammonium chloride solution. (Mix 90ml of 0.16M NH₄Cl and 10ml of 09.17M Tris-HCl pH 7.65; adjusted to pH 7.2 with dilute HCl). Cells were held in this solution for two minutes at room temperature followed by recovery of appropriate cells by centrifugation in fetal calf serum solution. The preparation was washed three times in 50ml of Hank's Balanced Salt Solution. About 5x10⁷ cells were then introduced into a 75ml tissue culture flask containing 17,500 units of recombinant IL-2 (Cetus Corp.) ^ RPMI 1640 ^ 10% fetal calf serum ^ 0.03% glutamine ^ streptomycin (100µg/ml) ^ penicillin (100 units/ml) ^ 0.1 mM nonessential amino acids ^ 1 µm sodium pyruvate ^ 5x10⁻⁵M of 2-mercaptoethanol ^ gentamycin (5µg/ml) ^ fungizone (0.5µg/ml) and the cells incubated for three days at 37°C in a 5% CO₂ environment. The flasks were then agitated and the cell suspension (nonadherent cells) was centrifuged at 1500rpm for 10min at room temperature. The resulting preparation contained primarily T-cells as demonstrated by expression of theta antigen. The cells assumed a dark granular color relative to identical control cells which were not treated with IL-2, and served as the source of antineoplastin. Extraction Procedure Peptides were solubilized from LAK cells utilizing an acid ethanol extraction procedure (Roberts, et al ., supra ). Cells were homogenized in a solution (4ml/g: 4°C) containing 375ml of 95% (v/v) ethanol and 7.5ml of concentrated HCl, with 33mg of phenylmethylsulfonyl fluoride and 56 trypsin-inhibitory units of aprotinin from bovine lung as protease inhibitors. The volume was adjusted to 6ml/g with distilled water and extracted overnight by gentle agitation with a magnetic stir bar at 4° followed by centrifugation. The supernatant was pooled and adjusted to pH 5.2 with conce. ammonium hydroxide. To the solution was added 1ml of 2M ammonium acetate buffer, pH 5.2, per 100ml of extract. A precipitate resulted which was removed by centrifugation, and the supernatant was mixed with 4 volumes of cold anhydrous ether and 2 volumes of cold ethanol (-20°C) and maintained for 24hr. The resulting precipitate was collected by centrifugation and lyophilized to dryness. Reverse Phase High Performance Liquid Chromatography High performance liquid chromatography was performed as previously described (Marquardt and Todaro, supra ). Separations were achieved utilizing a µ-Bondapak C₁₈ column (10mm particle size, 0.39x30cm, Water R Associates, Milford, CT). The mobile phase was 0.05% aqueous trifluoroacetic acid, and the mobile phase modifier was acetonitrile containing 0.045% trifluoroacetic acid. The gradient was 0 to 60% acetonitrile at 2hr at 1.5ml/min flow rate. The molecular weight was determined for the 42-43% acetonitrile eluting peptide(s) from a C₁₈ µ-Bondapak column using two tandem linked TSK250 columns (Biorad R ) calibrated with known polypeptide standards. The product had an apparent molecular weight of 15 to 22kD as determined by TSK250 HPLC sizing chromatography (45% acetonitrile, 0.05% trifluoroacetic acid). The product eluted from a C₁₈ µ-Bondapak column at 42-43% (uncorrected value) acetonitrile in 0.05% aqueous trifluoroacetic acid, pH 1.9. The product was found to be acid stable as only minimal activity was lost after treatment at low pH. The activity of the antineoplastin as a cytostatic agent for tumors was determined as follows: Growth Inhibitor Assay. Tumor growth inhibition assay was a modification of the assay previously described (Iwata, et al ., Cancer Research (1985) 45 :2689-2694). Tumor cells were subcultured on 96-well tissue culture plates (Nunc R 167008) in 50µl of complete medium at a density of 1x10⁴ cells/well. Aliquots from column fractions to be assayed for activity were transferred to sterile 12x75mm tubes (Falcon R 2058) containing 50µl of a 1mg/ml solution of bovine serum albumin (Sigma R A-6003) in 1M acetic acid and lyophilized. Immediately prior to assay, the lyophilized sample was resuspended in 200µl of completed medium and assayed in triplicate with 50µl of the resuspended sample added to each well. Cells were incubated for 72hr at 37°C in a humidified 5% CO₂-95% air atmosphere followed by a 24hr incubation with 100µl of complete medium containing [¹²⁵I] dUdr (1µCi/ml) (Amersham R IM.355V). Monolayers were washed once with phosphate-buffered saline, fixed for 10min in methanol, and air dried for 30min. The [¹²⁵I] dUdr incorporated by the cells was solubilized with 200µl 1M NaOH incubated at 65°C for 1hr. The samples were absorbed with Titertec (R) plugs, and the plugs were counted. The above results demonstrate that a novel natural product can be obtained by the induction of T-lymphocytes, particularly natural killer cells employing a lymphokine, such as IL-2. The resulting produce is found to have cytostatic activity specifically directed to neoplastic cells. Thus, the subject compounds can be used for the preparation of antibodies which can be diagnostic for the presence of the subject compounds, which may be indicative of the presence of neoplastic cells in a host, the activity of the immune system, particularly the T-cells, or more particularly the natural killer cells. The subject compounds can be used for reducing the proliferation of neoplastic cells in vitro and in vivo by itself, as well as in combination with other neoplastic arresting agents.

Claims: A composition comprising antineoplastin of at least 10% purity characterised by being capable of being induced by lymphokine activation of T-cells, having an apparent molecular weight in the range of 15 to 22kD as determined by sizing chromatography under conditions disfavoring aggregation and eluting from a C₁₈ µ-Bondapak column at 42-43% acetonitrile and 0.05% aqueous trifluoroacetic acid, pH 1.9 or biologically active fragments thereof. Antineoplastin of at least 10% purity, characterised by being capable of being induced by lymphokine activation of T-cells, having an apparent molecular weight in the range of 15 to 22kD as determined by sizing chromatography under conditions disfavoring aggregation and eluting from a C₁₈ µ-Bondapak column at 42-43% acetonitrile and 0.05% aqueous trifluoroacetic acid, pH 1.9 or biologically active fragments thereof. Antineoplastin of at least 90% purity and having a minimum activity for selected tumor cells from cancer of the lung, colon and breast capable of inhibiting the growth of 50% of the cells at 10-100ng per milliliter as determined by the growth inhibitor assay. A method of inhibiting the proliferation of neoplastic cells in vitro which comprises contacting said cells with a proliferation inhibiting amount of a composition according to any one of claims 1 to 3. A formulation for inhibiting the proliferation of neoplastic cells, which comprises a composition according to any one of claims 1 to 3 in a neoplastic cell proliferation inhibiting amount in a physiologically acceptable carrier. An antibody specific for a composition according to any one of claims 1 to 3, the antibody having been raised against an immunogen comprising said composition joined to an immunogenic protein. An immunogen comprising a composition according to any one of claims 1 to 3 covalently linked to a heterologous protein of at least 30kD. A method for producing a composition according to any one of claims 1 to 3, which comprises: growing T-cells in a culture medium containing a growth activating amount of lymphokine for a sufficient time for said T-cells to proliferate; harvesting said T-cells; lysing said cells; and separating said composition from other cellular components. A method according to claim 8, wherein said T-cells are natural killer cells and said lymphokine is IL-2. Acid-stable polypeptide of apparent molecular weight in the range of 15 to 22 kiloDaltons, as determined by sizing chromatography under conditions disfavouring aggregation and eluting from a C₁₈ µ-Bondapak column at 42-43% acetonitrile and 0.05% aqueous trifluoroacetic acid, pH 1.9, and isolatable from lymphokine-activated, e.g. interleukin-2-activated, T-lymphocytes, or biologically active fragments thereof. A method of producing a pharmaceutical composition comprising mixing a composition comprising antineoplastin of at least 10% purity characterised by being capable of being induced by lymphokine activation of T-cells, having an apparent molecular weight in the range of 15 to 22kD as determined by sizing chromatography under conditions disfavoring aggregation and eluting from a C₁₈ µ-Bondapak column at 42-43% acetonitrile and 0.05% aqueous trifluoroacetic acid, pH 1.9 or biologically active fragments thereof with a physiologically acceptable carrier. A method of producing an antibody specific for a composition comprising antineoplastin of at least 10% purity, capable of being induced by lymphokine activation of T-cells, having an apparent molecular weight in the range of 15 to 22kD as determined by sizing chromatography under conditions disfavoring aggregation and eluting from a C₁₈ µ-Bondapak column at 42-43% acetonitrile and 0.05% aqueous trifluoroacetic acid, pH 1.9 or biologically active fragments thereof, the method comprising raising an antibody against an immunogen comprising said composition joined to an immunogenic protein. A method of producing an immunogen comprising a composition comprising antineoplastin of at least 10% purity, capable of being induced by lymphokine activation of T-cells, having an apparent molecular weight in the range of 15 to 22kD as determined by sizing chromatography under conditions disfavoring aggregation and eluting from a C₁₈ µ-Bondapak column at 42-43% acetonitrile and 0.05% aqueous trifluoroacetic acid, pH 1.9 or biologically active fragments thereof, the method comprising linking said composition to a heterologous protein of at least 30kD.

Inventors: HELLSTROM, INGEGERD, HELLSTROM, KARL ERIC, TWARDZIK, DANIEL R.
Applicants: ONCOGEN LIMITED PARTNERSHIP
Application year: 1987
Main classification: A61K37
IPC codes: A61K38, C07K14, A61P35, A61K39, A61P37, C12P1, C12P21, C07K16, C12R1